Effect of Alpha-1-Adrenergic Agonist, Midodrine for the Management of Long-Standing Neurogenic Shock in Patient with Cervical Spinal Cord Injury: a Case Report
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Suplento1 Volumen 71 En
S1 Volumen 71 Mayo 2015 Revista Española de Vol. 71 Supl. 1 • Mayo 2015 Vol. Clínica e Investigación Órgano de expresión de la Sociedad Española de SEINAP Investigación en Nutrición y Alimentación en Pediatría Sumario XXX CONGRESO DE LA SOCIEDAD espaÑOLA DE CUIDADOS INTENSIVOS PEDIÁTRICOS Toledo, 7-9 de mayo de 2015 MESA REDONDA: ¿HACIA DÓNDE VAMOS EN LA MESA REDONDA: EL PACIENTE AGUDO MONITORIZACIÓN? CRONIFICADO EN UCIP 1 Monitorización mediante pulsioximetría: ¿sólo saturación 47 Nutrición en el paciente crítico de larga estancia en UCIP. de oxígeno? P. García Soler Z. Martínez de Compañón Martínez de Marigorta 3 Avances en la monitorización de la sedoanalgesia. S. Mencía 53 Traqueostomía, ¿cuándo realizarla? M.A. García Teresa Bartolomé y Grupo de Sedoanalgesia de la SECIP 60 Los cuidados de enfermería, ¿un reto? J.M. García Piñero 8 Avances en neuromonitorización. B. Cabeza Martín CHARLA-COLOQUIO SESIÓN DE PUESTA AL DÍA: ¿ES BENEFICIOSA LA 64 La formación en la preparación de las UCIPs FLUIDOTERAPIA PARA MI PACIENTE? españolas frente al riesgo de epidemias infecciosas. 13 Sobrecarga de líquidos y morbimortalidad asociada. J.C. de Carlos Vicente M.T. Alonso 68 Lecciones aprendidas durante la crisis del Ébola: 20 Estrategias de fluidoterapia racional en Cuidados experiencia del intensivista de adultos. J.C. Figueira Intensivos Pediátricos. P. de la Oliva Senovilla Iglesias 72 El niño con enfermedad por virus Ébola: un nuevo reto MESA REDONDA: INDICADORES DE CALIDAD para el intensivista pediátrico. E. Álvarez Rojas DE LA SECIP 23 Evolución de la cultura de seguridad en UCIP. MESA REDONDA: UCIP ABIERTAS 24 HORAS, La comunicación efectiva. -
Anti-Hypotensive Effects of M6434, an Orally Active a 1-Adrenoceptor Agonist, in Rats
Anti-Hypotensive Effects of M6434, an Orally Active a 1-Adrenoceptor Agonist, in Rats Tatsuroh Dabasaki, Masato Shimojo, Hiroshi Ishikawa and Akio Uemura Fuji Central Research Laboratory, Mochida Pharmaceutical Co., Ltd., 722 Jimba-aza-Uenohara, Gotemba, Shizuoka 412, Japan Received December 19, 1991 Accepted February 17, 1992 ABSTRACT-The anti-hypotensive effects of M6434 were evaluated and compared with those of other orally active sympathomimetics in rats. Oral administration of M6434 (0.5-2.0 mg/kg) and midodrine (1.0 5.0 mg/kg) also produced a dose-related increase in mean arterial pressure in normotensive rats. The pressor effect of M6434 was about 4 times more potent than that of midodrine. Both M6434 and midodrine caused a dose-dependent decrease in heart rate. The pressor effect of M6434 (1.0 mg/kg) did not diminish after its repeated administration for 7 days. The pretreatment with M6434 (0.5 1.0 mg/kg) and midodrine (2.0 5.0 mg/kg) improved the orthostatic index in the experimental model of postural hypotension in rats. The effect of M6434 on postural hypotension was about 5 times more po tent than that of midodrine. Intravenously injected M6434 (3-300pg/kg) produced a dose-dependent increase in the blood pressure of pithed rats. These results suggest that M6434 possesses a potent anti hypotensive activity which is superior to that of midodrine, and M6434 may be useful in the treatment of essential and postural hypotension. Keywords: M6434, a 1-Agonist, Midodrine, Postural hypotension, Orthostatic index M6434, 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imida in clinical therapy. -
Guidelines for NON - CRITICAL CARE Staff Common Vasoactive Drugs These Drugs Are Used to Maintain Cardiovascular Stability
Guidelines for NON - CRITICAL CARE staff Common vasoactive drugs These drugs are used to maintain cardiovascular stability. The full guide to administration can be found on BSUH infonet > intensive care unit > clinical guidelines > inotropes These drugs MUST be given via a central venous catheter. Be given via a ‘dedicated’ line (several vasoactives can run together in one lumen of a CVC) with a 2, 3 or 4 lumen connector. given via an ICU specific syringe driver – these allow you to change the rate without pausing the infusion. All ICU pumps have ICU or HDU spray-painted on them. Be ‘double pumped’ ie: when changing syringe, the old and new infusions run concurrently to prevent loss of infusion during change UNLESS ‘RAPID CHANGE- OVER’ TECHNIQUE IS USED, DUE TO LACK OF AVAILABLE PUMPS These drugs MUST NOT be paused, stopped or disconnected suddenly – they have a short half-life and pausing/stopping/disconnection may cause rapid CVS deterioration or arrest UNLESS ‘RAPID CHANGE-OVER’ TECHNIQUE IS USED, DUE TO LACK OF AVAILABLE PUMPS be given as a bolus, or bolused via the pump – this could cause rapid CVS instability run with ANY drug other than a vasoactive drug COMMON VASOACTIVES NORADRENALINE – vasopressor: causes vasoconstriction and used to improve BP USES: sepsis, septic shock, severe hypotension not resolved with fluid ADRENALINE – inotrope: increases contractility, raises BP and HR USES: sepsis, septic shock, severe bradycardia DOBUTAMINE – intrope and vasodilator: increases contractility and reduces cardiac work USES: -
Effectiveness of Midodrine Treatment in Patients with Recurrent Vasovagal
Europace (2011) 13, 1639–1647 CLINICAL RESEARCH doi:10.1093/europace/eur200 Syncope and Implantable Loop Recorders Effectiveness of Midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial) Downloaded from Jacobus J.C.M. Romme1, Nynke van Dijk2, Ingeborg K. Go-Scho¨ n3,4, Johannes B. Reitsma1, and Wouter Wieling3* 1Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands; 2Department of General Practice/ Family Medicine, 3 4 Academic Medical Center, Amsterdam, The Netherlands; Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands; and Bmeye Cardiovascular http://europace.oxfordjournals.org/ Monitoring B.V., Academic Medical Center, Amsterdam, The Netherlands Received 26 January 2011; accepted after revision 2 June 2011; online publish-ahead-of-print 13 July 2011 Aims Initial treatment of vasovagal syncope (VVS) consists of advising adequate fluid and salt intake, regular exercise, and physical counterpressure manoeuvres. Despite this treatment, up to 30% of patients continue to experience regular episodes of VVS. We investigated whether additional Midodrine treatment is effective in these patients. ..................................................................................................................................................................................... Methods In our study, patients with at least three syncopal and/or severe pre-syncopal recurrences during non-pharmacologi- and results cal treatment were eligible to receive double-blind cross-over treatment starting either with Midodrine or placebo. at Universiteit van Amsterdam on November 15, 2011 Treatment periods lasted for 3 months with a wash-out period of 1 week in-between. At baseline and after each treatment period, we collected data about the recurrence of syncope and pre-syncope, side effects, and quality of life (QoL). -
Pediatric Shock
REVIEW Pediatric shock Usha Sethuraman† & Pediatric shock accounts for significant mortality and morbidity worldwide, but remains Nirmala Bhaya incompletely understood in many ways, even today. Despite varied etiologies, the end result †Author for correspondence of pediatric shock is a state of energy failure and inadequate supply to meet the metabolic Children’s Hospital of Michigan, Division of demands of the body. Although the mortality rate of septic shock is decreasing, the severity Emergency Medicine, is on the rise. Changing epidemiology due to effective eradication programs has brought in Carman and Ann Adams new microorganisms. In the past, adult criteria had been used for the diagnosis and Department of Pediatrics, 3901 Beaubien Boulevard, management of septic shock in pediatrics. These have been modified in recent times to suit Detroit, MI 48201, USA the pediatric and neonatal population. In this article we review the pathophysiology, Tel.: +1 313 745 5260 epidemiology and recent guidelines in the management of pediatric shock. Fax: +1 313 993 7166 [email protected] Shock is an acute syndrome in which the circu- to generate ATP. It is postulated that in the face of latory system is unable to provide adequate oxy- prolonged systemic inflammatory insult, overpro- gen and nutrients to meet the metabolic duction of cytokines, nitric oxide and other medi- demands of vital organs [1]. Due to the inade- ators, and in the face of hypoxia and tissue quate ATP production to support function, the hypoperfusion, the body responds by turning off cell reverts to anaerobic metabolism, causing the most energy-consuming biophysiological acute energy failure [2]. -
Drugs-Biologicals FORMULARY for INTERNET PAGE 12 26 18
AVG ITEM Average Patient Item Charge Code Description BIL AWP /pkg COST Price 25000041 SODIUM and POTASSIUM BICARBONATE TBEF UD $3.61 $0.12 $1.00 25000054 GLIMEPIRIDE TAB 1 MG UD $8.25 $0.11 $1.30 25000086 amLODIPine TAB 5 MG UD $8.65 $0.06 $1.00 25000087 AMMONIA AROMATIC SOLN 15 % (W/V) UD $3.53 $0.17 $1.00 25000090 AMOXICILLIN CAP 500 MG UD $20.12 $0.19 $1.00 25000102 ABACAVIR TAB 300 MG UD $507.10 $8.45 $16.90 25000103 ACAMPROSATE TBEC 333 MG UD $182.38 $0.80 $1.76 25000104 ACARBOSE TAB 25 MG UD $16.70 $0.27 $1.00 25000106 ACETAMINOPHEN SUPP 120 MG UD $5.09 $0.42 $1.00 25000108 ACETAMINOPHEN SUPP 325 MG UD $4.91 $0.44 $1.00 25000109 ACETAMINOPHEN TAB 325 MG UD $12.39 $0.02 $1.00 25000111 ACETAMINOPHEN TAB 500 MG UD $2.34 $0.02 $1.00 25000112 ACETAMINOPHEN SUPP 650 MG UD $3.83 $0.17 $1.00 25000113 ACETAMINOPHEN SOLN 650 MG/20.3 ML UD $75.74 $0.48 $1.22 25000117 ACETAMINOPHEN-CODEINE TAB 300-30 MG UD $12.41 $0.09 $1.00 25000121 ACETYLCYSTEINE SOLN 200 MG/ML (20 %) UD $18.18 $7.66 $15.32 25000140 ALBUTEROL SULFATE NEBU 2.5MG/3ML (0.083 %) UD $8.58 $0.29 $1.00 25000147 ALLOPURINOL TAB 100 MG UD $18.45 $0.12 $1.00 25000150 ALPRAZolam TAB 0.25 MG UD $8.87 $0.09 $1.00 25000151 ALPRAZolam TAB 0.5 MG UD $4.16 $0.04 $1.00 25000182 AMIODARONE TAB 200 MG UD $15.70 $0.20 $1.00 25000184 AMITRIPTYLINE TAB 10 MG UD $8.73 $0.06 $1.00 25000186 AMITRIPTYLINE TAB 25 MG UD $17.46 $0.08 $1.00 25000188 AMITRIPTYLINE TAB 50 MG UD $34.90 $0.16 $1.00 25000205 HYDROCORTISONE ACETATE SUPP 25 MG UD $127.30 $5.75 $11.50 25000206 HEMORRHOIDAL SUPPOSITORY SUPP 0.25 -
Mechanical Ventilation Guide
MAYO CLINIC MECHANICAL VENTILATION GUIDE RESP GOALS INITIAL MONITORING TARGETS FAILURE SETTINGS 6 P’s BASIC HEMODYNAMIC 1 BLOOD PRESSURE SBP > 90mmHg STABILITY PEAK INSPIRATORY 2 < 35cmH O PRESSURE (PIP) 2 BAROTRAUMA PLATEAU PRESSURE (P ) < 30cmH O PREVENTION PLAT 2 SAFETY SAFETY 3 AutoPEEP None VOLUTRAUMA Start Here TIDAL VOLUME (V ) ~ 6-8cc/kg IBW PREVENTION T Loss of AIRWAY Female ETT 7.0-7.5 AIRWAY / ETT / TRACH Patent Airway MAINTENANCE Male ETT 8.0-8.5 AIRWAY AIRWAY FiO2 21 - 100% PULSE OXIMETRY (SpO2) > 90% Hypoxia OXYGENATION 4 PEEP 5 [5-15] pO2 > 60mmHg 5’5” = 350cc [max 600] pCO2 40mmHg TIDAL 6’0” = 450cc [max 750] 5 VOLUME 6’5” = 500cc [max 850] ETCO2 45 Hypercapnia VENTILATION pH 7.4 GAS GAS EXCHANGE BPM (RR) 14 [10-30] GAS EXCHANGE MINUTE VENTILATION (VMIN) > 5L/min SYNCHRONY WORK OF BREATHING Decreased High Work ASSIST CONTROL MODE VOLUME or PRESSURE of Breathing PATIENT-VENTILATOR AC (V) / AC (P) 6 Comfortable Breaths (WOB) SUPPORT SYNCHRONY COMFORT COMFORT 2⁰ ASSESSMENT PATIENT CIRCUIT VENT Mental Status PIP RR, WOB Pulse, HR, Rhythm ETT/Trach Position Tidal Volume (V ) Trachea T Blood Pressure Secretions Minute Ventilation (V ) SpO MIN Skin Temp/Color 2 Connections Synchrony ETCO Cap Refill 2 Air-Trapping 1. Recognize Signs of Shock Work-up and Manage 2. Assess 6Ps If single problem Troubleshoot Cause 3. If Multiple Problems QUICK FIX Troubleshoot Cause(s) PROBLEMS ©2017 Mayo Clinic Foundation for Medical Education and Research CAUSES QUICK FIX MANAGEMENT Bleeding Hemostasis, Transfuse, Treat cause, Temperature control HYPOVOLEMIA Dehydration Fluid Resuscitation (End points = hypoxia, ↑StO2, ↓PVI) 3rd Spacing Treat cause, Beware of hypoxia (3rd spacing in lungs) Pneumothorax Needle D, Chest tube Abdominal Compartment Syndrome FLUID Treat Cause, Paralyze, Surgery (Open Abdomen) OBSTRUCTED BLOOD RETURN Air-Trapping (AutoPEEP) (if not hypoxic) Pop off vent & SEE SEPARATE CHART PEEP Reduce PEEP Cardiac Tamponade Pericardiocentesis, Drain. -
Wednesday, July 10, 2019 4:00Pm
Wednesday, July 10, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – July 10, 2019 DATE: July 3, 2019 NOTE: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the July meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – Appendix B Action Item – Vote to Prior Authorize Jornay PM™ [Methylphenidate Extended-Release (ER) Capsule], Evekeo ODT™ [Amphetamine Orally Disintegrating Tablet (ODT)], Adhansia XR™ (Methylphenidate ER Capsule), and Sunosi™ (Solriamfetol Tablet) – Appendix C Action Item – Vote to Prior Authorize Balversa™ (Erdafitinib) – Appendix D Action Item – Vote to Prior Authorize Annovera™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System), Bijuva™ (Estradiol/Progesterone Capsule), Cequa™ (Cyclosporine 0.09% Ophthalmic Solution), Corlanor® (Ivabradine Oral Solution), Crotan™ (Crotamiton 10% Lotion), Gloperba® (Colchicine Oral Solution), Glycate® (Glycopyrrolate Tablet), Khapzory™ (Levoleucovorin Injection), Qmiiz™ ODT [Meloxicam Orally Disintegrating Tablet (ODT)], Seconal Sodium™ (Secobarbital -
Approach to Shock.” These Podcasts Are Designed to Give Medical Students an Overview of Key Topics in Pediatrics
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on “Approach to Shock.” These podcasts are designed to give medical students an overview of key topics in pediatrics. The audio versions are accessible on iTunes or at www.pedcases.com/podcasts. Approach to Shock Developed by Dr. Dustin Jacobson and Dr Suzanne Beno for PedsCases.com. December 20, 2016 My name is Dustin Jacobson, a 3rd year pediatrics resident from the University of Toronto. This podcast was supervised by Dr. Suzanne Beno, a staff physician in the division of Pediatric Emergency Medicine at the University of Toronto. Today, we’ll discuss an approach to shock in children. First, we’ll define shock and understand it’s pathophysiology. Next, we’ll examine the subclassifications of shock. Last, we’ll review some basic and more advanced treatment for shock But first, let’s start with a case. Jonny is a 6-year-old male who presents with lethargy that is preceded by 2 days of a diarrheal illness. He has not urinated over the previous 24 hours. On assessment, he is tachycardic and hypotensive. He is febrile at 40 degrees Celsius, and is moaning on assessment, but spontaneously breathing. We’ll revisit this case including evaluation and management near the end of this podcast. The term “shock” is essentially a ‘catch-all’ phrase that refers to a state of inadequate oxygen or nutrient delivery for tissue metabolic demand. This broad definition incorporates many causes that eventually lead to this end-stage state. Basic oxygen delivery is determined by cardiac output and content of oxygen in the blood. -
Midodrine As Adjunctive Support for Treatment of Refractory Hypotension
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Anstey, Matthew H., Bradley Wibrow, Tharusan Thevathasan, Brigit Roberts, Khushi Chhangani, Pauline Yeung Ng, Alexander Levine, Alan DiBiasio, Todd Sarge, and Matthias Eikermann. 2017. “Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).” BMC Anesthesiology 17 (1): 47. doi:10.1186/s12871-017-0339-x. http://dx.doi.org/10.1186/ s12871-017-0339-x. Published Version doi:10.1186/s12871-017-0339-x Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32072012 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Anstey et al. BMC Anesthesiology (2017) 17:47 DOI 10.1186/s12871-017-0339-x STUDY PROTOCOL Open Access Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial) Matthew H. Anstey1,2, Bradley Wibrow1,2, Tharusan Thevathasan3, Brigit Roberts1, Khushi Chhangani3, Pauline Yeung Ng3, Alexander Levine4, Alan DiBiasio5, Todd Sarge6 and Matthias Eikermann3,7* Abstract Background: Patients admitted to intensive care units (ICU) are often treated with intravenous (IV) vasopressors. -
FACT SHEET for HEALTHCARE PROVIDERS Coronavirus Emergency Use of the Coviage System During the COVID-19 Pandemic Disease 2019 September 24, 2020 (COVID-19)
FACT SHEET FOR HEALTHCARE PROVIDERS Coronavirus Emergency Use of the COViage System During the COVID-19 Pandemic Disease 2019 September 24, 2020 (COVID-19) This Fact Sheet informs you of the significant known and What do I need to know about COVID-19 treatment? potential risks and benefits of the emergency use of the Current information on COVID-19 infection, including COViage System (or “COViage”) for use by healthcare case definitions and information about clinical signs and providers (HCP) in the hospital setting for adult patients symptoms and/or epidemiological criteria, is available on (18 years of age or older who are admitted to the the CDC website listed at the end of this fact sheet. hospital) with confirmed COVID-19 (based on a positive . PCR test result) for the computation of proprietary patient status indices referred to as Respiratory What is the COViage System? Decompensation Status and Hemodynamic Instability The COViage System is a non-interventional software Status as an adjunct to patient monitoring during the program that uses vital signs and patient demographic COVID-19 outbreak. The COViage indices provide HCP data from EMR systems. It uses models derived from with predictive screening information as a diagnostic aid machine learning on patient data from EMRs to calculate to assist with the early identification of COVID-19 the likelihood of the occurrence of certain clinically patients who are likely to be diagnosed with significant events, specifically, hemodynamic instability hemodynamic instability or respiratory decompensation, or respiratory decompensation. It then notifies HCP of which are common complications associated with patients who, according to the algorithm, are expected to COVID-19. -
Hypothesis Spinal Shock and `Brain Death': Somatic Pathophysiological
Spinal Cord (1999) 37, 313 ± 324 ã 1999 International Medical Society of Paraplegia All rights reserved 1362 ± 4393/99 $12.00 http://www.stockton-press.co.uk/sc Hypothesis Spinal shock and `brain death': Somatic pathophysiological equivalence and implications for the integrative-unity rationale DA Shewmon*,1 1Pediatric Neurology, UCLA Medical School, Los Angeles, California, USA The somatic pathophysiology of high spinal cord injury (SCI) not only is of interest in itself but also sheds light on one of the several rationales proposed for equating `brain death' (BD) with death, namely that the brain confers integrative unity upon the body, which would otherwise constitute a mere conglomeration of cells and tissues. Insofar as the neuropathology of BD includes infarction down to the foramen magnum, the somatic pathophysiology of BD should resemble that of cervico-medullary junction transection plus vagotomy. The endocrinologic aspects can be made comparable either by focusing on BD patients without diabetes insipidus or by supposing the victim of high SCI to have pre-existing therapeutically compensated diabetes insipidus. The respective literatures on intensive care for BD organ donors and high SCI corroborate that the two conditions are somatically virtually identical. If SCI victims are alive at the level of the `organism as a whole', then so must be BD patients (the only signi®cant dierence being consciousness). Comparison with SCI leads to the conclusion that if BD is to be equated with death, a more coherent reason must be adduced than that the body as a biological organism is dead. Keywords: brain death; spinal cord injury; spinal shock; integrative functions; somatic integrative unity; organism as a whole Introduction Spinal shock is a transient functional depression of the society; its legal de®nition is culturally relative, and structurally intact cord below a lesion, following acute most modern societies happen to have chosen to spinal cord injury (SCI).